References
Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’Er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460: 753–757.
Luan ZL, Cui XH, Xu H, Lu HY, Li YY, Lu TL, et al. Association of MSI2 gene polymorphism with age-at-onset of schizophrenia in a Chinese population. Neurosci Bull 2017, 33: 731–733.
Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, et al. HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in schizophrenia. J Clin Psychopharmacol 2015, 35: 220–227.
Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004, 23: 540–545.
Pohjalainen T, Rinne J, Någren K, Lehikoinen P, Anttila K, Syvälahti E, et al. The A1 allele of the human D 2 dopamine receptor gene predicts low D 2 receptor availability in healthy volunteers. Mol Psychiatry 1998, 3: 256–260.
Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010, 167: 763–772.
Gamazon ER, Segrè AV, van de Bunt M, Wen X, Xi HS, Hormozdiari F, et al. Using an atlas of gene regulation across 44 human tissues to inform complex disease-and trait-associated variation. Nat Genet 2018, 50: 956–967.
Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009, 17: 946–957.
Ji X, Takahashi N, Saito S, Ishihara R, Maeno N, Inada T, et al. Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neurosci Lett 2008, 435: 95–98.
Mcmahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006, 78: 804–814.
Lin JY, Jiang MY, Kan ZM, Chu Y. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis. J Affect Disord 2014, 168: 430–438.
Staeker J, Leucht S, Laika B, Steimer W. Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genet Test Mol Biomarkers 2014, 18: 20–31.
Laika B, Leucht S, Heres S, Schneider H, Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2010, 10: 20–29.
Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, et al. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol 2010, 25: 228–231.
Pitychoutis PM, Belmer A, Moutkine I, Adrien J, Maroteaux LJN. Mice lacking the serotonin Htr 2B receptor gene present an antipsychotic-sensitive schizophrenic-like phenotype. Neuropsychopharmacology 2015, 40: 2764–2773.
Selvaraj S, Arnone D, Cappai A, Howes OJN, Reviews B. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev 2014, 45: 233–245.
Acknowledgements
This work was supported by the National Basic Research Development Program (2016YFC0904300), the National Natural Science Foundation of China (81630030 and 81461168029), and the 1.3.5 Project for Disciplines of Excellence of West China Hospital, Sichuan University (ZY2016103 and ZY2016203), China.
Author information
Authors and Affiliations
Consortia
Corresponding authors
Ethics declarations
Conflict of interest
All authors claim that there are no conflicts of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhao, L., Wang, H., Zhang, Y. et al. Interaction Between Variations in Dopamine D2 and Serotonin 2A Receptor is Associated with Short-Term Response to Antipsychotics in Schizophrenia. Neurosci. Bull. 35, 1102–1105 (2019). https://doi.org/10.1007/s12264-019-00432-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12264-019-00432-2